NCT04994015 Parkinson's Foundation PD GENEration Genetic Registry
| NCT ID | NCT04994015 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Parkinson's Foundation |
| Condition | Parkinson's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 25,000 participants |
| Start Date | 2020-12-20 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25,000 participants in total. It began in 2020-12-20 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Development of a central repository for PD-related genomic data for future research.
Eligibility Criteria
Inclusion Criteria: * Study Population 1: PWP (open for recruitment) 1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis. 2. Willingness to undergo genetic testing, and choose to be informed of genetic testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7). 3. Capacity to give full informed consent in writing or electronically, and have read and signed the informed consent forms (ICFs) based on site clinician's determination. 4. Able to perform study activities (including completion of either online, in-person or paper surveys). Study Population 2: People at risk of developing PD (not open for recruitment) 1\. Family members of Study Population 1 may be invited to participate in the study if confirmatory genetic testing is deemed necessary by the genetic testing laboratory. Exclusion Criteria: 1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus. 2. Individuals who have received a blood transfusion within the past 3 months. 3. Individuals who have active hematologic malignancies such as lymphoma or leukemia. 4. Individuals who have had a bone marrow transplant within the past 5 years. 5. Under the age of 18
Contact & Investigator
James Beck, PhD
PRINCIPAL INVESTIGATOR
Parkinson's Foundation
Frequently Asked Questions
Who can join the NCT04994015 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04994015 currently recruiting?
Yes, NCT04994015 is actively recruiting participants. Contact the research team at kghosh@parkinson.org for enrollment information.
Where is the NCT04994015 trial being conducted?
This trial is being conducted at Birmingham, United States, Chandler, United States, Phoenix, United States, Fayetteville, United States and 11 additional locations.
Who is sponsoring the NCT04994015 clinical trial?
NCT04994015 is sponsored by Parkinson's Foundation. The principal investigator is James Beck, PhD at Parkinson's Foundation. The trial plans to enroll 25,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.